‘GLP-1 RECEPTOR IN ORAL FORM WILL BE MADE AVAILABLE FOR DIABETICS’

“We plan to continue innovating in therapy and patient solutions to help manage the uncontrolled growth of diabetes in India, the lack of care, awareness, and the challenges faced regarding access to products. There are several products in our pipeline, including the first-of-its-kind GLP-1 receptor in the oral form that will be made accessible to people living with diabetes in India in the near future.” - VIKRANT SHROTRIYA, Managing Director and Corporate Vice President, Novo Nordisk India, Bengaluru